Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | NEON-1 & NEON-2: ALPN-202 alone or with pembrolizumab in patients with advanced malignancies

ALPN-202 is a first-in-class conditional CD28 costimulator and dual PD-L1/CTLA-4 inhibitor. Meredith McKean, MD, Sarah Cannon Research Institute, Nashville, TN, comments on initial data from the NEON-1 trial (NCT04186637), a Phase I study of ALPN-202 monotherapy in patients with advanced malignancies and outlines preliminary data of ALPN-202 in combination with pembrolizumab. Preclinical data shows improvement in tumor cell reduction with the combination of ALPN-202 with pembrolizumab. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.